KFAS
AUPH icon

Keating Financial Advisory Services’s Aurinia Pharmaceuticals AUPH Stock Holding History

Keating Financial Advisory Services’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Buy
856
+202
+31% +$3.23K ﹤0.01% 1107
2026
Q1 		$9.69K Buy
654
+645
+7,167% +$9.43K ﹤0.01% 1143
2025
Q4 		$144 Buy
+9
New +$128 ﹤0.01% 2101

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's AUPH Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Aurinia Pharmaceuticals (AUPH) stake by 31% in Q2 2026, buying an estimated $3.23K and bringing the position to 856 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1107.

Keating Financial Advisory Services first reported a position in AUPH in Q4 2025 and has held it in 3 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Keating Financial Advisory Services held 856 shares of Aurinia Pharmaceuticals worth $14.5K as of Q2 2026.
  • Keating Financial Advisory Services bought 202 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $3.23K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1107 holding.
  • Keating Financial Advisory Services first reported a position in Aurinia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.